Please login to the form below

Not currently logged in
Email:
Password:

Final NICE ‘no’ for Celgene’s Imnovid

England’s pricing watchdog says multiple myeloma drug is just too expensive for the NHS

Imnovid pill packshot 

NICE has issued final draft guidance rejecting Celgene's next-generation multiple myeloma pill Imnovid (pomalidomide) on account of its high price.

The watchdog was looking at the drug in a late-stage setting, and in combination with the steroid dexamethasone, after the failure of a number of other medicines for the disease on what is a complicated patient treatment pathway.

NICE currently recommends Celgene's Thalidimod (thalidomide) for most patients as a first-line treatment, and Takeda/Janssen's Velcade (bortezomib) for people who are unable to take Thalidimod and also as an option after the first treatment has stopped working.

Meanwhile, for people who have received two prior treatments, NICE also recommends Revlimid (lenalidomide), another multiple myeloma (MM) medicine from Celgene.

Imnovid is the next generation version of both Thalidimod and Revlimid and this appraisal considers the use of the drug for treating MM after a third or subsequent relapse.

Celgene was hoping to gain a third yes for its new medicine, but NICE, in line with its previous draft guidance, is not recommending it be paid for by England's NHS. 

Commenting on the guidance, Sir Andrew Dillon, NICE's chief executive, said: “Unfortunately we cannot recommend pomalidomide as the analyses from Celgene, the company that markets the drug, showed that it does not offer enough benefit to justify its high price.”

NICE says the final draft guidance is now with consultees - including Celgene and cancer charities - who have the opportunity to appeal against it. This means that Celgene now has just one final shot at getting its drug recommended before a final decision is published next month, although it is unlikely NICE will change its mind.

The list price of a pack of 21 tablets costs just under £9,000 - NICE say that this equals a QALY (Quality Adjusted Life Year) of more than £50,000. The pricing body will not usually recommend a medicine with a QALY higher than £20,000 - £30,000.

Celgene says its drug could treat a patient population of 669 in England. Multiple myeloma is the second most common blood cancer and affects around 9,900 people in the UK and Ireland.

The disease causes plasma cells to replicate uncontrollably and accumulate in the bone marrow, disrupting the production of normal blood cells. Nearly all patients diagnosed with multiple myeloma will eventually relapse and require treatment with an alternative therapy.

Article by
Ben Adams

26th March 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics